MEDTRONIC PLC

Medtronic PLC’s strategy in China, analyst shifts from buy to hold, and global investor interest reveal how the medical‑tech giant is navigating growth, margin pressure, and portfolio inclusion.

Medtronic’s FDA clearance of the OmniaSecure lead for left bundle branch pacing lifts shares slightly, boosting its conduction‑system portfolio and positioning the company ahead in the growing CRT‑LBB market.

Medtronic PLC unveils a CFO briefing and a strategic partnership with GE HealthCare to boost structural heart and minimally invasive device markets, promising growth and transparency for investors.

Medtronic’s MiniMed IPO targets $7 bn, with a $34 bn valuation, to expand diabetes tech and boost access while driving outcome‑based reimbursement.

Medtronic PLC’s Q3 earnings show 3.8% revenue growth, yet margin pressure prompts mixed analyst views. Discover how value‑based care, the Hugo system, and digital health investments shape the company’s long‑term prospects.

Medtronic PLC eyes earnings growth with new Indian campaign and leadership in embolic protection and CSF devices, boosting investor confidence and market reach.

Medtronic’s FDA‑cleared Stealth AXiS system delivers 94 % screw‑placement accuracy, cuts imaging exposure by 30 %, and may shave 20 % off spine‑surgery time—boosting safety and reducing costs.

Medtronic PLC faces a complex mix of antitrust judgment and divergent analyst views, yet its diverse product line and R&D pipeline offer resilience amid regulatory scrutiny.

Medtronic’s CE‑marked Affera Sphere‑360 offers a safer, faster alternative for treating atrial fibrillation, backed by strong EU data and new U.S. trials.

Medtronic PLC partners with Precision Neuroscience to create a real‑time neural‑imaging platform that fuses robotics and imaging, boosting tumor resection accuracy while driving growth in telemetry and M&A opportunities.